SOLANA BEACH, Calif. - Artelo Biosciences , Inc. (NASDAQ:ARTL), a clinical-stage biopharmaceutical company, has been selected as a finalist in the Johnson & Johnson (NYSE:NYSE:JNJ) Innovation Challenge. The challenge focuses on discovering novel treatments for atopic dermatitis, and Artelo presented its preclinical research on a potential therapy at an event in San Diego, California, on Sunday.
Artelo's research centers on ART26.12, a drug candidate targeting the Fatty-Acid Binding Protein 5 (FABP5), which is overexpressed in several dermatological conditions and is associated with inflammation and disease severity.
The company's preclinical studies have shown promising results in psoriasis models, where ART26.12 demonstrated a reduction in oxidative stress and inflammation in human epidermis samples, as well as decreased skin scaling and thickness in vivo.
"We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
He added that the selection validates the potential of Artelo's FABP5 target platform. Professor Saoirse O'Sullivan, Vice President of Translational Science at Artelo, highlighted the therapeutic promise of their FABP5 inhibitors for a range of indications, including dermatological conditions.
ART26.12 is also being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN), with an initial clinical study planned. Artelo's portfolio extends beyond ART26.12, with a library of small molecule FABP inhibitors that could potentially treat various conditions such as cancer, pain, and anxiety disorders.
Artelo is preparing to present its dermatology data at a scientific conference later this year, furthering the discourse on ART26.12's potential benefits.
The company's mission is to develop treatments that modulate lipid-signaling pathways, including the endocannabinoid system, to address unmet needs in diseases and conditions like anorexia, cancer, anxiety, pain, and inflammation.
The information in this article is based on a press release statement from Artelo Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.